Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis.

Prasanna Ananth, Annette Werger, Stephan Voss, Carlos Rodriguez-Galindo, Katherine A Janeway

Pediatric blood & cancer 2017 Jul

filter terms:

Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression-free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics. © 2016 Wiley Periodicals, Inc.

Citation

Prasanna Ananth, Annette Werger, Stephan Voss, Carlos Rodriguez-Galindo, Katherine A Janeway. Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatric blood & cancer. 2017 Jul;64(7)